Loading... Please wait...
Sort by:
  • Non Small Cell Lung Cancer (NSCLC): KOL Insight
    Learn More Non Small Cell Lung Cancer (NSCLC): KOL Insight
    Latest Update Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC), including; the FDA accepting Merck and Co.’s regulatory filing for Keytruda (pembrolizumab) in combination...
  • Multiple Sclerosis: Payer Insight
    Learn More Multiple Sclerosis: Payer Insight
    Latest Update Topics covered in this update include: payers’ approaches to the reimbursement of Ocrevus (ocrelizumab; Roche/Biogen) for relapsing remitting multiple sclerosis (RRMS) and primary progressive...
  • Psoriasis: KOL Insight
    Learn More Psoriasis: KOL Insight
    Latest Update This edition presents key opinion leader (KOL) views on recent developments in the moderate to severe psoriasis treatment market. Topics covered include: Janssen Biotech announcing new data from two...
  •  COPD: Update Bulletin [July 2016]
    Learn More COPD: Update Bulletin [July 2016]
    This edition presents key opinion leader (KOL) views on recent developments in the chronic obstructive pulmonary disease (COPD) market. Topics covered include the clinical relevance of the latest clinical trial data...
  • Cancer Immunotherapy (Payer): Update Bulletin [June 2016]
    Learn More Cancer Immunotherapy (Payer): Update Bulletin [June 2016]
    Gain new payer insights on the latest events with the potential to shape the cancer immunotherapy market. In this update, payers give their perspective on the potential reimbursement and coverage of Roche’s...
  • Malignant Melanoma: Update Bulletin [July 2016]
    Learn More Malignant Melanoma: Update Bulletin [July 2016]
    Gain new KOL insights on the latest events happening in malignant melanoma (MM): Array BioPharma’s submission of a New Drug Application (NDA) for binimetinib to the US Food and Drug Administration (FDA) in advanced...
  • Multiple Sclerosis: Update Bulletin [June 2016]
    Learn More Multiple Sclerosis: Update Bulletin [June 2016]
    Gain new KOL insights on the latest events happening in the multiple sclerosis (MS) treatment landscape. Topics covered include reactions to the Phase IIb/III MS-SPI/MS-ON trials of MedDay’s MD1003; the FDA...
  • Targeted Therapies in Asthma: Update Bulletin [July 2016]
    Learn More Targeted Therapies in Asthma: Update Bulletin [July 2016]
    This edition presents key opinion leader (KOL) views on recent developments in the asthma market. Topics covered include the latest clinical trial data presented by AstraZeneca and Teva at the 2016 American Thoracic...
  • Rheumatoid Arthritis: Update Bulletin [June 2016]
    Learn More Rheumatoid Arthritis: Update Bulletin [June 2016]
    Gain new KOL insights on the latest events happening in rheumatoid arthritis (RA) treatment landscape. Topics covered include reaction to the availability of a new biosimilar version of the anti-TNF, infliximab;...
  • Age-Related Macular Degeneration (AMD): KOL Insight
    Learn More Age-Related Macular Degeneration (AMD): KOL Insight
    Innovation on all fronts as drug-makers and doctors reimagine wAMD treatment Find out how next-generation VEGF inhibitors and other pipeline drugs will transform wet age-related macular degeneration (wAMD) treatment...
  • Idiopathic Pulmonary Fibrosis (IPF): KOL Insight
    Learn More Idiopathic Pulmonary Fibrosis (IPF): KOL Insight
    What’s on the KOL ‘wish list’ for the next generation of IPF treatments? Physicians currently only have two options for Idiopathic Pulmonary Fibrosis (IPF) sufferers: how do they decide between them?...
  • Multiple Myeloma: KOL Insight
    Learn More Multiple Myeloma: KOL Insight
    Latest Update This edition presents key opinion leader (KOL) views on recent developments in the multiple myeloma (MM) market. Topics covered include; Amgen’s announcement of positive results from a planned...
  • Chronic Lymphocytic Leukaemia: Update Bulletin [May 2016]
    Learn More Chronic Lymphocytic Leukaemia: Update Bulletin [May 2016]
    Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of Chronic Lymphocytic Leukaemia (CLL). Topics covered include expert opinions about the recent label expansion of...
  • Biosimilars in Oncology: Update Bulletin [May 2016]
    Learn More Biosimilars in Oncology: Update Bulletin [May 2016]
    This edition presents key opinion leader (KOL) views on recent developments in the oncology biosimilars market. Topics covered include Brazil’s drug regulator, Agência Nacional de Vigilância...
  • Hepatitis C: Update Bulletin [May 2016]
    Learn More Hepatitis C: Update Bulletin [May 2016]
    This edition presents key opinion leader (KOL) views on recent developments in the hepatitis C virus (HCV) treatment market. Topics covered include the potential for Gilead’s sofosbuvir/velpatasvir (SOF/VEL) to...
  • Dyslipidaemia: Update Bulletin [May 2016]
    Learn More Dyslipidaemia: Update Bulletin [May 2016]
    Gain new KOL insights on the latest events happening in Dyslipidaemia: Amgen’s new detailed data from the Phase III GAUSS-3 trial for Repatha; Sanofi and Regeneron’s Phase III ODYSSEY ESCAPE trial in...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved